Business Business: Shares of Alembic Pharmaceuticals rose 5.38 per cent to Rs 1285.60 per share on the BSE on Thursday ahead of the pharma major’s financial performance announcement. However, the stock lost all its gains and slipped in the red after the company announced its first quarter results for the financial year 2024-25 (Q1FY25). The company reported good growth in topline and bottomline on a year-on-year basis for April-June of FY25. The company reported revenue from operations of Rs 1,562 crore, a growth of 5 per cent over Rs 1,486 crore in the June quarter of FY24. Net profit also grew 10 per cent year-on-year to Rs 131 crore in Q1FY25 from Rs 119 crore in the corresponding quarter of the previous year. However, it witnessed a decline of 21 per cent as compared to Rs 166 crore in Q4FY24. The company’s earnings before interest, tax, depreciation and amortization (EBITDA) grew 14 per cent to Rs 239 crore, the company said in a statement. The company’s India branded business grew 9 per cent year-on-year to Rs 572 crore for the quarter. Apart from this, US generics grew 18 per cent to Rs 461 crore for the quarter. The company launched two products in the US market during the quarter. Alembic Pharma said the launch of recently approved products will drive growth in the US in the coming quarters. The company received 9 final approvals in Q1FY25.
Alembic Pharma Q1FY25 profit rises 10% to Rs 131 crore
